Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of UCN-01 in relapsed or refractory systemic anaplastic large cell and mature T-cell lymphomas.

Trial Profile

Phase II study of UCN-01 in relapsed or refractory systemic anaplastic large cell and mature T-cell lymphomas.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 May 2017

At a glance

  • Drugs UCN 01 (Primary)
  • Indications Extranodal NK-T-cell-lymphoma; Non-Hodgkin's lymphoma; T cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 01 May 2017 Status changed from completed to discontinued as IND was withdrawn by CTEP due to low accrual and cost of maintaining the IND.
    • 01 May 2017 Status changed from completed to discontinued as IND was withdrawn by CTEP due to low accrual and cost of maintaining the IND.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top